Chemotherapy for ovarian cancer: beyond paclitaxel plus carboplatin
Ozols, R.F.
Cancer Journal from Scientific American 5(6): 336-338
1999
ISSN/ISBN: 1081-4442 PMID: 10606473 Document Number: 511178
Document emailed within 1 workday
Related Documents
Skarlos, D.V.; Aravantinos, G.; Kosmidis, P.; Athanassiadis, A.; Stathopoulos, G.P.; Pavlidis, N.; Bafaloukos, D.; Karphathios, S.; Papakostas, P.; Bamia, C.; Fountzilas, G. 1997: Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study Seminars in Oncology 24(5 Suppl 15: S15Du Bois, A.; Lück, H.J.; Meier, W.; Möbus, V.; Costa, S.; Richter, B.; Warm, M.; Bauknecht, T.; Schröder, W.; Olbricht, S.; Nitz, U.; Jackisch, C. 1997: Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase IIi trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group Seminars in Oncology 24(5 Suppl 15: S15
Vapattanawong, P. 2006: A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer Journal of the Medical Association of Thailand 89(9): 1357-1361
Ozols, R.F. 2000: Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer Seminars in Oncology 27(3 Suppl 7: 3-7
Ota, T.; Takeshima, N.; Takizawa, K. 2011: Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly? European Journal of Gynaecological Oncology 32(5): 471-475
Kietpeerakool, C.; Tiyayon, J.; Suprasert, P.; Kanjanavanit, R.; Srisomboon, J. 2006: Benefit of electrocardiography during front-line combination paclitaxel and carboplatin chemotherapy for epithelial ovarian cancer Journal of the Medical Association of Thailand 89(11): 1805-1810
Mayerhofer, K.; Bodner-Adler, B.; Bodner, K.; Leodolter, S.; Kainz, C. 2000: Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity Anticancer Research 20(5c): 4047-4050
Ishikawa, M.; Nakayama, K.; Rahman, M.T.; Rahman, M.; Katagiri, H.; Katagiri, A.; Ishibashi, T.; Iida, K.; Nakayama, N.; Miyazaki, K. 2014: Therapy-related myelodysplastic syndrome and acute myeloid leukemia following chemotherapy (paclitaxel and carboplatin) and radiation therapy in ovarian cancer: a case report European Journal of Gynaecological Oncology 35(4): 443-448
Lehoczky, O.ó; Pulay, T.ás. 2003: Early results of first-line chemotherapy with paclitaxel and carboplatin in patients with epithelial ovarian carcinoma Orvosi Hetilap 144(28): 1381-1384
Kosmidis, P.; Mylonakis, N.; Fountzilas, G.; Samantas, E.; Athanassiadis, A.; Pavlidis, N.; Skarlos, D. 1997: Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study Seminars in Oncology 24(4 Suppl 12: S12
Ten Bokkel Huinink, W.; Veenhof, C.; Helmerhorst, T.; Bierhorst, F.; Dalesio, O.; Winograd, B.; Depauw, L.; Pinedo, H.M. 1995: Paclitaxel plus carboplatin in the treatment of ovarian cancer Seminars in Oncology 22(3 Suppl 6: 97-100
Ozols, R.F. 1999: Paclitaxel plus carboplatin in the treatment of ovarian cancer Seminars in Oncology 26(1 Suppl 2: 84-89
Yasuda, M.; Kimura, E.; Ochiai, K.; Tada, S.; Udagawa, Y.; Aoki, D.; Nozawa, S.; Kikuchi, Y.; Kita, T.; Nishida, M.; Tsunoda, H. 2001: Dose finding study of paclitaxel and carboplatin for ovarian cancer (JKTB) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 28(4): 493-498
Bolis, G. 1995: Pilot study with fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer Seminars in Oncology 22(6 Suppl 14: 32-34
Kietpeerakool, C.; Suprasert, P.; Srisomboon, J. 2005: Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer Journal of the Medical Association of Thailand 88(3): 301-306
Bolis, G.; Scarfone, G.; Villa, A.; Acerboni, S.; Siliprandi, V.; Guarnerio, P. 1997: A phase i trial with fixed-dose carboplatin and escalating doses of paclitaxel in advanced ovarian cancer Seminars in Oncology 24(1 Suppl 2: S2
Yokoyama, Y.; Shigeto, T.; Futagami, M.; Mizunuma, H. 2005: Syndrome of inappropriate secretion of anti-diuretic hormone following carboplatin-paclitaxel administration in a patient with recurrent ovarian cancer European Journal of Gynaecological Oncology 26(5): 531-532
Kaira, K.; Ishizuka, T.; Yanagitani, N.; Sunaga, N.; Hisada, T.; Mori, M. 2007: Effective combination chemotherapy of carboplatin and paclitaxel in the treatment of a recurrent small-cell lung cancer patient Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(2): 225-227
Wojciechowska-Lacka, A.; Markowska, J.; Skasko, E.; Kruczek, A.; Steffen, J. 2003: Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report) European Journal of Gynaecological Oncology 24(1): 21-24
Mito, A.; Yamasaki, M.; Ohashi, N.; Kajihara, T.; Nitta, T.; Awaya, H.; Ikegami, Y.; Arita, K-ichi. 2010: A retrospective study of carboplatin and weekly paclitaxel combination chemotherapy for elderly patients with advanced non-small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(9): 1707-1711